Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom
Table 1
Survival distribution inputs.
Pazopanib
Placebo
Reference
Weibull survival function parameters
PFS (months)
Lambda
0.1279
0.3714
PALETTE
Gamma
1.1252
1.0809
PALETTE
OS (months)
Lambda
0.0282
0.0469
PALETTE
Gamma
1.2341
1.1027
PALETTE
PPS (months)
Lambda
0.104
0.118
PALETTE
Gamma
0.902
0.898
PALETTE
Probability of death without disease progression (required for Markov cohort model)a
0.053
0
PALETTE
HR for PFS for pazopanib versus comparator
Ifosfamide
0.91 (95% CI, 0.73–1.14)
Sharma et al. 2013 [18] van Oosterom et al. 2002 [43]
Trabectedin
0.90 (95% CI, 0.76–1.07)
Sharma et al. 2013 [18] Demetri et al. 2009 [44] Garcia-Carbonero et al. 2005 [45] le Cesne et al. 2005 [46] Yovine et al. 2004 [47]
Gemcitabine + docetaxel
0.99 (95% CI, 0.70–1.40)
Sharma et al. 2013 [18] Hensley et al. 2008 [48] Pautier et al. 2012 [33]
CI: confidence interval; HR: hazard ratio; OS: overall survival; PFS: progression-free survival; PPS: postprogression survival. Same value was assumed for chemotherapies in indirect comparison.